Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026
One daysingle sourceOne outlet reported this, once - no second voice in this corpus.
All 1 reports on Fri, 9 October 2026
What it is about
Melyssa WeibleManish SaxenaTerry FergusonCatalys PacificElixir Health Public RelationsHypertension Specialist At Barts HealthLinkedinTerms Of ServiceDeputy Clinical CoExchange CommissionDrug AdministrationNasdaqUnited StatesRadnor, Pennsylvania, United StatesPennsylvania, United StatesManila, Manila, Philippines
Who published it, and when
How it spread - 1 original report
Fri, 9 October 2026
1 report- manilatimes.net13:09first to report
- New analyses from the pivotal Launch-HTN trial showed that 46% of participants with difficult-to-treat hypertension receiving lorundrostat 50 mg achieved the AHA/ACC Guideline systolic blood pressure target of